The Nuchal Translucency–Cardiac Connection

There is a moment that happens regularly in fetal cardiology referrals. A first-trimester scan shows an elevated nuchal translucency. The karyotype comes back normal. And somewhere along the way, the worry quietly dissolves — as though the chromosomes have spoken for the heart as well.

They have not.

Contents

What NT is actually measuring
The cardiac risk that persists after a normal karyotype
The diagnostic window that opens earlier
The lesions to keep in mind
What the guidelines recommend
What comes after the diagnosis
The practical point

What NT Is Actually Measuring

▼

Nuchal translucency reflects the accumulation of fluid in the subcutaneous space behind the fetal neck, measured between 11 and 13+6 weeks of gestation. It became widely known as a screening marker for chromosomal anomalies — particularly trisomy 21 — and that association is real and well-established.

But NT is not a chromosomal marker alone. Understanding what drives the fluid to accumulate in the first place is key to understanding why the heart is so often involved.

💡

Three mechanisms link elevated NT to cardiac pathology. Each works independently, and each points back to the heart as a potential source, not just a bystander.

Three mechanisms linking NT elevation to cardiac pathology

The three pathways: haemodynamic backpressure from cardiac failure raises venous pressure and blocks lymphatic drainage; arterial obstruction (e.g. aortic narrowing) redirects flow toward the head and neck; and shared embryological signalling between the cardiac chambers and jugular lymphatic sacs means genetic mutations can cause parallel malformations in both systems simultaneously.

Haemodynamic backpressure Transient diastolic cardiac failure raises central venous pressure, physically blocking normal lymphatic drainage into the jugular system. The fluid has nowhere to go.

Arterial obstruction Narrowing of the fetal aortic isthmus limits lower-body blood flow. High-pressure flow is redirected toward the head and neck, producing localised tissue oedema.

Shared embryology Endothelial cells forming the cardiac chambers share signalling pathways with the jugular lymphatic sacs. A single genetic mutation can cause concurrent malformations in both systems at once.

NT is therefore a marker of abnormal lymphatic drainage, altered cardiac function, and disrupted haemodynamic flow in early fetal life. The heart is not a bystander in this process. It is often the cause.

The Cardiac Risk That Persists After a Normal Karyotype

▼

The illusion of a normal karyotype versus the reality of cardiac risk

The clinical disconnect at a glance. A normal karyotype result addresses chromosomes only. It does not evaluate cardiac structure, haemodynamic function, or lymphatic drainage — each of which can be independently disrupted in a chromosomally normal fetus with elevated NT.

Once a chromosomal abnormality has been excluded, the background risk of congenital heart disease in the general population sits at roughly 0.8 to 1%. An elevated NT changes that number substantially — and the change is proportional to how elevated the NT is.

⚠️

The risk is proportional, not binary. There is no sudden jump at one specific threshold. Risk escalates continuously from 3.0 mm upward. This matters for the 3.0–3.4 mm group, who are often not referred.

~1%

General population
baseline CHD risk

1–3%

NT ≥ 3.0 mm
(above 95th centile)

~6%

NT ≥ 3.5 mm
(above 99th centile)

The exponential relationship between NT thickness and cardiac risk

The exponential risk curve. Note that the relationship is not linear — risk accelerates sharply above 3.0 mm. An NT above the 95th centile predicts approximately 37% of major congenital heart defects in chromosomally normal fetuses (Sotiriadis et al., 2013). The standard referral threshold of ~1% (three times background population risk) is crossed decisively at 3.5 mm.

Key finding

A pooled analysis of 637 cases of CHD with known karyotype found that among chromosomally normal fetuses, nearly 23% had an NT of 3.5 mm or above. The elevated NT was distributed across all subtypes of CHD — left heart lesions, right heart lesions, outflow tract anomalies, septal defects, and complex abnormalities — with no predilection for any single group.

The practical message is that elevated NT does not flag a particular cardiac diagnosis. It flags cardiac risk in general, across the full spectrum of structural heart disease.

The Diagnostic Window That Opens Earlier

▼

There is a second, often overlooked benefit to taking the NT-cardiac connection seriously: timing of diagnosis. In chromosomally normal fetuses with an NT of 3.5 mm or above, the mean gestational age at diagnosis of CHD was 16.1 weeks — compared to 22.1 weeks in those with a normal NT.

Weeks gained with NT-prompted echocardiographyMean diagnosis at 16.1 weeks vs 22.1 weeks at standard anatomy scan. In the context of counselling and planning, six weeks is not a minor detail.

The six-week diagnostic advantage of NT-prompted echocardiography

Two clinical pathways compared. Track 1 (standard): normal karyotype result, no early echo, CHD diagnosed at mean 22.1 weeks at the anatomy scan. Track 2 (NT-prompted): elevated NT triggers early fetal echocardiography at 14–18 weeks, CHD diagnosed at mean 16.1 weeks — providing a six-week window for counselling, genetic testing, delivery planning, and neonatal surgical preparation.

This six-week compression has real clinical consequences. Consider what can be done in that window:

16–17 weeks

Cardiac diagnosis confirmed

Anatomy is visible for major structural lesions. Major defects identifiable on early echo before the anatomy scan window.

17–19 weeks

Genetic workup and counselling

Chromosomal microarray and targeted RASopathy panel results returned. Full counselling possible before viability threshold.

20–22 weeks

Comprehensive fetal echo

Mandatory follow-up regardless of early echo result. Progressive lesions — particularly left-sided obstructive lesions — may not be fully apparent in the early window.

Third trimester

Delivery planning at tertiary centre

Neonatal surgical team informed, delivery centre selected, family preparation completed — all earlier than the standard pathway allows.

✓
Important note on early echo: A clear scan at 16–18 weeks does not cancel the requirement for a comprehensive fetal echocardiogram at 20–22 weeks. Progressive lesions such as coarctation of the aorta may not be apparent in the early window and require the later scan for definitive assessment.

The Lesions to Keep in Mind

▼

Elevated NT does not flag one specific defect. It is a marker of global cardiac structural vulnerability. Defects are distributed across all subtypes, and the spectrum changes with the degree of NT elevation.

The anatomical spectrum of cardiac defects associated with elevated NT

The spectrum of associated cardiac defects stratified by NT elevation. Mild elevation (2.5–3.5 mm) is predominantly associated with simple shunts (VSD, ASD), which account for approximately 20% of findings. Critical elevation (> 3.5 mm) shows an equal distribution of haemodynamically significant lesions including HLHS, coarctation, TOF, and AVSD.

⚠️

Do not assume mild lesions. Hypoplastic left heart syndrome and coarctation of the aorta both appear in the elevated NT context. The elevated NT is sometimes the first — and only — early signal of a haemodynamically critical lesion.

Defects associated with elevated NT in chromosomally normal fetuses include:

Ventricular Septal Defect

Atrial Septal Defect

Hypoplastic Left Heart

Coarctation of Aorta

Tetralogy of Fallot

AVSD

Isolated Valve Anomalies

Outflow Tract Anomalies

Red chips indicate haemodynamically critical lesions requiring delivery planning at a tertiary centre.

What the Guidelines Recommend

▼

Fetal echocardiography referral guideline categories

Current referral framework based on published international guidelines. Category 1 (absolute indication) applies to NT ≥ 3.5 mm. Category 2 (considered indication) applies to NT 3.0–3.4 mm, particularly when ductus venosus flow is abnormal. Isolated IVF and isolated single umbilical artery with normal NT no longer carry a guideline-based indication for fetal echocardiography.

The 2023 updated guidelines from the American Society of Echocardiography are clear on this point. Fetal echocardiography is recommended when NT is 3.5 mm or above, and should be considered when NT is between 3.0 and 3.5 mm.

NT ≥ 3.5 mm	Absolute indication. Risk clears the 1% referral threshold at approximately 6%. Fetal echocardiography is recommended without qualification. (ASE Class I; AHA/SMFM agreement)
NT 3.0–3.4 mm	Considered indication. Risk sits at 1–3%. Strongly advised, especially when ductus venosus flow is abnormal. Abnormal DV flow in this range pushes diagnostic yield for major CHD to approximately 15%.
NT < 3.0 mm	Standard anatomy scan sufficient in the absence of other risk factors. Standard mid-trimester anatomy survey remains important and should include a good cardiac view.

📋

The underlying threshold principle: Fetal echocardiography is warranted when the estimated risk of CHD exceeds approximately three times the background population risk, which corresponds to roughly 1%. An NT of 3.5 mm in a chromosomally normal fetus crosses that threshold with room to spare. The ductus venosus waveform is the key adjunct in the 3.0–3.4 mm grey zone.

What Comes After the Diagnosis

▼

The prognosis for CHD identified in the context of elevated NT is not the same as for CHD identified through standard screening. The mortality data show a consistent and widening gap.

Postnatal mortality comparison: CHD with normal versus elevated NT

Postnatal mortality at one and five years for CHD with normal versus elevated NT. The gap widens over time. The higher mortality in the elevated NT cohort is driven not by the cardiac defect alone, but by a higher rate of co-existing extracardiac anomalies (22.7% vs 14.2%) and underlying submicroscopic genetic syndromes that standard karyotyping does not detect.

This difference is not driven by the cardiac defect in isolation. It reflects the broader genetic and structural burden that elevated NT represents. Two additional investigations have a meaningful yield in this population even after a normal conventional karyotype:

Chromosomal Microarray (CMA) For isolated NT ≥ 3.5 mm with normal karyotype, CMA yields a pathogenic copy-number variant in 3.5–6.1% of cases. These are submicroscopic deletions and duplications invisible to standard karyotyping.

Targeted RASopathy Panel Even after a normal CMA, testing for Noonan syndrome (RAS-MAPK pathway mutations, notably PTPN11) yields a diagnosis in 1.0–1.4% of isolated NT ≥ 3.5 mm cases. This rises to approximately 14% when concurrent structural anomalies are present.

⚠️

A normal karyotype and a normal CMA do not fully close the genetic question in a fetus with NT ≥ 3.5 mm and a cardiac defect. The RASopathy panel is the third layer, and its yield is clinically significant.

The Practical Point

▼

Normal chromosomes do not equal a normal heart. Elevated NT is an independent cardiac risk marker, and the data supporting fetal echocardiography in this setting have been accumulating for two decades. The referral conversation is worth having, and worth having early.

Chromosomes ≠ Heart Elevated NT is a powerful, independent marker for major structural CHD and submicroscopic genetic anomalies, completely independent of a normal standard karyotype or cfDNA result.

Watch the 3.0–3.4 mm grey zone A rigid 3.5 mm cutoff misses critical defects. Risk escalates exponentially from 3.0 mm. Use ductus venosus flow and gestational-age percentile nomograms to guide referral decisions in this range.

Time is clinical value Elevated NT prompts early fetal echocardiography at 14–18 weeks. This shifts the diagnostic timeline by six weeks, fundamentally transforming parental counselling, genetic testing, and delivery planning.

A note on the mid-trimester scan

A normal NT in a chromosomally normal fetus does not eliminate the need for a good cardiac view at the mid-trimester anatomy scan. And an elevated NT that returns a normal karyotype has not been cleared — it has answered only one question out of several. The fetal heart deserves its own assessment, on its own terms, by the 20th week at the latest.

References
Sotiriadis A et al. Ultrasound Obstet Gynecol 2013 • Smrcek JM et al. Am J Obstet Gynecol 2005 • American Society of Echocardiography: Guidelines for Fetal Echocardiography 2023